Daniel Auclair, President of Hematocure, shared a post on X:
“Wojciech Jurczak at ASH25 on pirtobrutinib versus BendaR in frail elderly frontline CLL/SLL patients (BRUIN CLL-313 study).
Possibly the most active single agent BTKi versus its comparator in a randomized study in this population.”
More posts featuring Daniel Auclair on OncoDaily.
